Doctors involved in the study say the medication works by preventing the virus from being able to anchor itself in human immune cells.
They say the drug -- still in early stages of development -- has reduced the amount of HIV infection in the blood by as much as 95 percent.
Their results, which come from an early stage trial of 18 patients, are published in the journal Science Translational Medicine.
